STOCK TITAN

LeMaitre Vascular, Inc. - LMAT STOCK NEWS

Welcome to our dedicated page for LeMaitre Vascular news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on LeMaitre Vascular stock.

LeMaitre Vascular, Inc. (Nasdaq: LMAT) is a leading provider of medical devices and implants for the treatment of peripheral vascular disease, a condition that affects over 200 million people globally. The company develops, manufactures, and markets disposable and implantable vascular devices aimed at addressing the needs of vascular surgeons. LeMaitre Vascular offers a diversified product portfolio that includes angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.

Headquartered in Burlington, Massachusetts, LeMaitre's products are utilized during open vascular surgeries, primarily focusing on several anatomical areas such as the carotid, lower extremities, upper extremities, and aorta. The company's lower extremities product line generates the highest revenue, followed by the carotid product line. In recent financial updates, the company reported significant growth in sales across various product categories including bovine patches, valvulotomes, and carotid shunts.

LeMaitre Vascular continues to demonstrate robust financial health. For Q3 2023, the company reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies. Operating income for Q4 2023 was up 46%, reflecting strong sales growth and improved gross margins. In addition, LeMaitre has a share repurchase program and regularly pays dividends to its shareholders, exemplifying its commitment to shareholder value.

Furthermore, LeMaitre Vascular is focused on expanding its global footprint. Sales in the Americas, EMEA, and APAC regions have shown substantial growth, contributing significantly to the company's revenue. The company also emphasizes compliance with global regulatory requirements, ensuring that its products meet stringent quality standards.

LeMaitre frequently engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. The company remains committed to innovation and development, constantly working on new projects to enhance its product offerings and address emerging market needs.

For more information about LeMaitre Vascular and its latest updates, visit their official website at www.lemaitre.com.

Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) will participate in four investor conferences in March 2024, including Oppenheimer Healthcare MedTech & Services Conference, Barclays Global Healthcare Conference, Roth Conference, and KeyBanc Life Sciences & MedTech Investor Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.53%
Tags
conferences
-
News
Rhea-AI Summary
LeMaitre (LMAT) reports strong Q4 2023 results with a 19% sales increase, $0.16/share dividend, and positive guidance for 2024. Key financial highlights include a 46% growth in operating income, a 50% increase in net income, and a 49% rise in diluted EPS. The company's gross margin improved to 68.1%, driven by higher selling prices and operational efficiencies. LeMaitre also announced a share repurchase program and a quarterly dividend of $0.16/share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.41%
Tags
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (LMAT) is set to announce its fourth quarter 2023 financial results on February 27, 2024, with a conference call scheduled to discuss the results, business highlights, and company outlook.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) CFO to Present at 26th Annual Needham Growth Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
conferences
-
Rhea-AI Summary
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will be participating in three upcoming investor conferences in November. The conferences include Jefferies London Healthcare Conference on November 14 in London, UK, where the Chief Financial Officer will present at 11:00 AM GMT. Stifel's 2023 Healthcare Conference will also take place on November 14 in New York City, with the President presenting at 1:50 PM ET. Lastly, the Piper Sandler 35th Annual Healthcare Conference will be held on November 29 in New York City, where the President will present at 2:10 PM ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.53%
Tags
conferences
-
News
Rhea-AI Summary
LeMaitre (Nasdaq:LMAT) reported Q3 2023 results with sales of $47.4mm, a 21% increase from Q3 2022. Gross margin increased to 65.0%. Operating income grew by 49% to $9.2mm. Net income was $7.5mm, a 38% increase. The company announced a $0.14/share quarterly dividend. Q4 2023 guidance projects sales of $48.0mm - $50.0mm and operating income of $9.4mm - $10.7mm.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
Rhea-AI Summary
LeMaitre Vascular to release Q3 2023 financial results
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
-
Rhea-AI Summary
LeMaitre Vascular, Inc. to present at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
conferences
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
conferences

FAQ

What is the current stock price of LeMaitre Vascular (LMAT)?

The current stock price of LeMaitre Vascular (LMAT) is $107.97 as of November 22, 2024.

What is the market cap of LeMaitre Vascular (LMAT)?

The market cap of LeMaitre Vascular (LMAT) is approximately 2.4B.

What products does LeMaitre Vascular offer?

LeMaitre Vascular offers a range of medical devices including angioscopes, balloon catheters, carotid shunts, phlebectomy devices, vascular grafts, vascular patches, and vessel closure systems.

Where is LeMaitre Vascular headquartered?

LeMaitre Vascular is headquartered in Burlington, Massachusetts.

In which medical areas are LeMaitre's products primarily used?

LeMaitre's products are primarily used in open vascular surgeries targeting the carotid, lower extremities, upper extremities, and aorta.

What was the company's financial performance in Q3 2023?

In Q3 2023, LeMaitre reported a 21% increase in sales and a 49% rise in operating income, driven by price increases and operational efficiencies.

How does LeMaitre Vascular engage with its investors?

LeMaitre Vascular engages with investors through earnings calls, providing transparency about its financial performance and strategic outlook. Investors can access these through the company's website.

What regions contribute significantly to LeMaitre's revenue?

LeMaitre's revenue is significantly contributed by sales in the Americas, EMEA, and APAC regions.

Does LeMaitre Vascular pay dividends to its shareholders?

Yes, LeMaitre Vascular regularly pays dividends to its shareholders.

What recent financial achievements has LeMaitre Vascular reported?

LeMaitre reported significant growth across various product lines, including bovine patches, valvulotomes, and carotid shunts, with strong sales and improved gross margins in recent quarters.

How does LeMaitre ensure the quality of its products?

LeMaitre ensures the quality of its products by complying with global regulatory requirements and maintaining stringent quality standards.

Where can I find more information about LeMaitre Vascular?

More information about LeMaitre Vascular can be found on their official website at www.lemaitre.com.

LeMaitre Vascular, Inc.

Nasdaq:LMAT

LMAT Rankings

LMAT Stock Data

2.41B
20.50M
8.84%
94.18%
3.49%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States of America
BURLINGTON